<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473642</url>
  </required_header>
  <id_info>
    <org_study_id>2007002</org_study_id>
    <nct_id>NCT00473642</nct_id>
  </id_info>
  <brief_title>Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration</brief_title>
  <official_title>A Prospective Pilot Study of Reduced Fluence Photodynamic Therapy With Visudyne® (Verteporfin) in Combination With Lucentis™ (Ranibizumab) for the Treatment of Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oklahoma State University Center for Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oklahoma State University Center for Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot study the researchers will evaluate the safety and efficacy of 50% reduced
      fluence PDT combination therapy with ranibizumab. The researchers hope to gain information
      regarding the use of reduced fluence PDT combination therapy. The information gained from
      this pilot study may prompt further definitive studies comparing the safety and efficacy of
      both standard fluence PDT combination therapy, reduced fluence PDT combination therapy, and
      ranibizumab monotherapy.

      The study will compare the use of combination therapy with ranibizumab and verteporfin PDT to
      ranibizumab alone in patients with exudative age-related macular degeneration (AMD). All
      patients will receive three consecutive monthly treatments with ranibizumab. Patients will be
      randomized 1:1:1 to 3 groups. Patients randomized to group 1 will receive only ranibizumab.
      Patients randomized to group 2 will also receive one treatment with reduced fluence (50%
      fluence) verteporfin PDT at day 0. Patients randomized to group 3 will also receive one
      treatment with standard fluence verteporfin PDT. All patients will also be evaluated for
      possible retreatment with ranibizumab and verteporfin PDT according to established criteria.
      Thirty patients will be recruited from one U.S. sites. Randomization will occur at the time
      of entry into the study. Follow-up will continue until month 12 (from day 0) in all subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Letters Gained of Best Corrected Visual Acuity Using ETDRS Protocol</measure>
    <time_frame>12 months</time_frame>
    <description>Visual acuity is often measured using a chart called the ETDRS chart (Early Treatment Diabetic Retinopathy Study). A letter score is calculated based on the number of letters that can be correctly identified from specified distances. Higher letter scores correspond to better visual acuity. Lower letter scores mean poorer visual acuity. In this study, the number of letters gained over the course of the study. In other words the baseline visual acuity in letters was subtracted from the visual acuity in letters measured at the 12 month visit providing a letter score of vision gain or vision loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Retreatment After Loading Doses, Average Number of Retreatments Over 12 Months, Central Macular Thickness on OCT, the Number of Recurrent CNV, the Number of Patients With Persistent CNV After the Mandatory Loading Doses.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Age-Related Maculopathy</condition>
  <condition>Choroidal Neovascularization</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Fluence Photodynamic Therapy combined with ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>intravitreal administered ranibizumab 0.5 mg in 0.05 mL</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin</intervention_name>
    <description>Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin</intervention_name>
    <description>Verteporfin with standard fluence photodynamic therapy (50 J/cm2)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Visudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female Patients &gt; 50 years of age.

          2. Patients with primary subfoveal CNV secondary to AMD documented on IVFA and/or OCT.

          3. Patient with BCVA of 20/40 to 20/320 in the study eye using Early Treatment Diabetic
             Retinopathy Study (ETDRS) charts. See definition of ETDRS charts.

          4. If both eyes are eligible, only one eye will be evaluated in the study. The eye with
             lesser visual acuity will be selected as the study eye.

          5. Patients must be able and willing to provide written informed consent.

        Exclusion Criteria:

          1. Patients receiving prior treatment in the study eye with verteporfin, any focal laser
             photocoagulation, vitrectomy, or intravitreous injection of antiangiogenic
             medications, including triamcinolone, pegaptanib, bevacizumab, or ranibizumab.

          2. Neovascular membrane from any other retinal disease such as myopic degeneration,
             histoplasmosis, retinal angiomatous proliferation, or other ocular inflammatory
             disease.

          3. Choroidal neovascular membrane greater than 9 disc diameters in size.

          4. Previous posterior vitrectomy in the study eye.

          5. Concurrent disease in the study eye that could compromise visual acuity or require
             medical or surgical intervention during the study period.

          6. Pregnant women or premenopausal women not using adequate contraception.

          7. History of allergy to fluorescein, Visudyne, Lucentis.

          8. Inability to comply with study or follow up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott J Westhouse, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma State University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Townsend, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma State University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Saurino, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma State University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eagle Mountain Vision</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <results_first_submitted>September 20, 2011</results_first_submitted>
  <results_first_submitted_qc>October 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2012</results_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oklahoma State University Center for Health Sciences</investigator_affiliation>
    <investigator_full_name>Scott J. Westhouse</investigator_full_name>
    <investigator_title>Ophthalmologist</investigator_title>
  </responsible_party>
  <keyword>Ranibizumab</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Verteporfin</keyword>
  <keyword>Visudyne</keyword>
  <keyword>Photodynamic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Fluence PDT</title>
          <description>Standard Fluence Photodynamic Therapy combined with ranibizumab</description>
        </group>
        <group group_id="P2">
          <title>50% Fluence PDT</title>
          <description>Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab</title>
          <description>Ranibizumab monotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Fluence PDT</title>
          <description>Standard Fluence Photodynamic Therapy combined with ranibizumab</description>
        </group>
        <group group_id="B2">
          <title>50% Fluence PDT</title>
          <description>Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab</title>
          <description>Ranibizumab monotherapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.9" spread="3.1"/>
                    <measurement group_id="B2" value="73.4" spread="2.1"/>
                    <measurement group_id="B3" value="76.3" spread="2.8"/>
                    <measurement group_id="B4" value="74" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in BCVA of ETDRS Letters From Baseline at 12 Months</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Retreatment After Loading Doses, Average Number of Retreatments Over 12 Months, Central Macular Thickness on OCT, the Number of Recurrent CNV, the Number of Patients With Persistent CNV After the Mandatory Loading Doses.</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Letters Gained of Best Corrected Visual Acuity Using ETDRS Protocol</title>
        <description>Visual acuity is often measured using a chart called the ETDRS chart (Early Treatment Diabetic Retinopathy Study). A letter score is calculated based on the number of letters that can be correctly identified from specified distances. Higher letter scores correspond to better visual acuity. Lower letter scores mean poorer visual acuity. In this study, the number of letters gained over the course of the study. In other words the baseline visual acuity in letters was subtracted from the visual acuity in letters measured at the 12 month visit providing a letter score of vision gain or vision loss.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard Fluence PDT</title>
            <description>Standard Fluence Photodynamic Therapy combined with ranibizumab</description>
          </group>
          <group group_id="O2">
            <title>50% Fluence PDT</title>
            <description>Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab</title>
            <description>Ranibizumab monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Letters Gained of Best Corrected Visual Acuity Using ETDRS Protocol</title>
          <description>Visual acuity is often measured using a chart called the ETDRS chart (Early Treatment Diabetic Retinopathy Study). A letter score is calculated based on the number of letters that can be correctly identified from specified distances. Higher letter scores correspond to better visual acuity. Lower letter scores mean poorer visual acuity. In this study, the number of letters gained over the course of the study. In other words the baseline visual acuity in letters was subtracted from the visual acuity in letters measured at the 12 month visit providing a letter score of vision gain or vision loss.</description>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="6.3"/>
                    <measurement group_id="O2" value="7.6" spread="4"/>
                    <measurement group_id="O3" value="16.4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Fluence PDT</title>
          <description>Standard Fluence Photodynamic Therapy combined with ranibizumab</description>
        </group>
        <group group_id="E2">
          <title>50% Fluence PDT</title>
          <description>Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab</title>
          <description>Ranibizumab monotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <description>greater than 2 months after last ranibizumab</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>cardiopulmonary arrest</sub_title>
                <description>following hip fracture and complications greater than 2 months after ranibizumab</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was limited by a small number of subjects. Additionally, several subjects did not meet the 12 month study endpoint. These subjects were included in the final analysis if their last visit was within 2 months of the final endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Scott Westhouse, DO</name_or_title>
      <organization>Retina Specialists of Michigan</organization>
      <phone>616-954-2020</phone>
      <email>s.westhouse@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

